Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Sarcoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Neoplasms 8 Carcinoma, Hepatocellular 8 Thyroid Neoplasms 5 Melanoma 5 Endometrial Neoplasms 5 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Cancer, Papillary 3 Colorectal Neoplasms 3 Adenocarcinoma, Follicular 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma 2 Glioma 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid cancer, medullary 1 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Thyroid Carcinoma, Anaplastic 1 Solid Tumors 1 Sarcoma 1

Interventions

Doxorubicin 31 Ifosfamide 22 pazopanib 17 Gemcitabine 15 Cyclophosphamide 14 Radiotherapy 13 pembrolizumab 11 Filgrastim 10 Docetaxel 10 Vincristine 9 Sirolimus 9 Etoposide 9 Irinotecan 8 Bevacizumab 8 Sorafenib 7 temsirolimus 6 olaratumab 6 eribulin 6 Mesna 6 cixutumumab 5 Trabectedin 5 Radiosurgery 5 Radiation 5 Magnetic Resonance Spectroscopy 5 Granulocyte Colony-Stimulating Factor 5 tazemetostat 4 etoposide phosphate 4 Temozolomide 4 Nivolumab 4 Ipilimumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡